grant | 2025 - 2026
Allele selective LRRK2 targeted antisense oligonucleotide therapeutic development for Parkinsons Disease
Perron Institute for Neurological and Translational Science
Grant no. 22599.
grant | 2025 - 2028
Co-development of genetic targets and antisense oligonucleotides for the treatment of amyotrophic lateral sclerosis
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 23136.
grant | 2024 - 2025
CMMIT Capability Development Projects
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 22197.
grant | 2024 - 2025
Does Charge Matter - Investigating the Biodistribution of Morpholinos and Thio-Morpholinos
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21949.
grant | 2024 - 2026
Establishment of an early-stage clinical trial manufacturing enabling facility for small RNA therapeutics.
Western Australian Department of Health
Grant no. 22373.
grant | 2024 - 2024
Syn suppression as a therapy for Parkinsons and motor neuron diseases
Perron Institute for Neurological and Translational Science
Grant no. 21961.
grant | 2022 - 2024
A targeted therapy for juvenile-onset Parkinsons disease patients arising from PARK2 mutations using splice-switching antisense oligonucleotides
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 21283.
grant | 2022 - 2027
Loren Flynn Perron SPA
General
Grant no. 20762.
grant | 2022 - 2027
Perron SPA Anthony Akkari
General
Grant no. 20760.
grant | 2022 - 2024
Perron SPA Dunhui (Oliver) Li
General
Grant no. 20894.
grant | 2022 - 2023
Perron SPA Rita Mejzini
General
Grant no. 20897.
grant | 2021 - 2025
Antisense oligonucleotides targeted to the p62 PB1 domain as a potential therapy in ALS.
General
Grant no. 20203.
grant | 2020 - 2021
Antisense oligonucleotide targeting of p62-mediated TDP-43 pathology as a treatment for amyotrophic lateral sclerosis
General
Grant no. 19825.
grant | 2020 - 2021
AO drugs in Parkinson's disease
Perron Institute for Neurological and Translational Science (Australia, Nedlands) - WANRI
Grant no. 19818.
grant | 2020 - 2023
Pre-clinical development of a SOD1 genetic therapy in sporadic ALS: enabling investigational new drug submission
General
Grant no. 19597.
grant | 2020 - 2021
Risk genes in sporadic Inclusion Body Myositis (IBM)
General
Grant no. 19819.
grant | 2020 - 2021
Validation of motor neuron disease patient olfactory neural stem cells as a drug evaluation platform
General
Grant no. 19968.
grant | 2020 - 2021
WA MND Research Consortium:
General
Grant no. 19668.
grant | 2019 - 2019
Investigating the mechanism and therapeutic potential of a SOD1-ALS modifier
General
Grant no. 18587.
grant | 2018 - 2022
Perron Sponsored position extension - Anthony Akkari
General
Grant no. 18177.
grant | 2018 - 2019
QUT led - Accelerating precision therapies through digital infrastructure for adaptive trials and trial-ready cohort studies
General
Grant no. 17947.
grant | 2018 - 2020
Rita Mejzini - Perron Institute Prestige Scholarship
General
Grant no. 18179.
grant | 2017 - 2018
Tony Akkari - Shiraz sponsored position
General
Grant no. 17468.
grant | 2017 - 2022
Tony Akkari Sponsored Position WANRI
General
Grant no. 17466.
grant
Perron appointment - Dr Loren Price
General
Grant no. 18123.
grant
Perron SPA - Yuval Gurfinkel
Perron Institute for Neurological and Translational Science
Grant no. 22949.